(-)-Caryophyllene Oxide

(-)-Caryophyllene Oxide

SCHEMBL676309

C=C1CCC2O[C@]2(C)CC[C@@H]2[C@@H]1CC2(C)C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 10/20 1.00
FTH1 P02794 1/20 1.00
CYP2C9 P11712 1/20 1.00
CYP2C19 P33261 1/20 1.00
CNR2 P34972 2/20 0.51
PPARA Q07869 2/20 0.51
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
ALDH1A1 P00352 1/20 0.47
PTPN1 P18031 1/20 0.41
HSP90AA1 P07900 1/20 0.40
USP2 O75604 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
(-)-Caryophyllene Oxide SCHEMBL16489852 1.00 CYP3A4 (1.00) CYP3A4FTH1CYP2C9CYP2C19CNR2
(-)-Caryophyllene Oxide SCHEMBL18788522 1.00 CYP3A4 (1.00) CYP3A4FTH1CYP2C9CYP2C19CNR2
(-)-Caryophyllene Oxide SCHEMBL1532444 1.00 CYP3A4 (1.00) CYP3A4FTH1CYP2C9CYP2C19CNR2
(-)-Caryophyllene Oxide SCHEMBL127077 1.00 CYP3A4 (1.00) CYP3A4FTH1CYP2C9CYP2C19CNR2
(-)-Caryophyllene Oxide SCHEMBL24110118 1.00 CYP3A4 (1.00) CYP3A4FTH1CYP2C9CYP2C19CNR2
(-)-Caryophyllene Oxide SCHEMBL17857878 1.00 CYP3A4 (1.00) CYP3A4FTH1CYP2C9CYP2C19CNR2
(-)-Caryophyllene Oxide SCHEMBL24110084 1.00 CYP3A4 (1.00) CYP3A4FTH1CYP2C9CYP2C19CNR2
(-)-Caryophyllene Oxide SCHEMBL16769854 1.00 CYP3A4 (1.00) CYP3A4FTH1CYP2C9CYP2C19CNR2
(-)-Caryophyllene Oxide SCHEMBL21349931 1.00 CYP3A4 (1.00) CYP3A4FTH1CYP2C9CYP2C19CNR2
(-)-Caryophyllene Oxide SCHEMBL26189380 1.00 CYP3A4 (1.00) CYP3A4FTH1CYP2C9CYP2C19CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240066005-A1 FORMULATIONS FOR TREATING CLUSTER SYMPTOMS ASSOCIATED WITH AUTISM SPECTRUM DISORDER ILERA THERAPEUTICS LLC 2024-02-29 US disclosed
US-20230242569-A1 PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS THE SCRIPPS RESEARCH INSTITUTE 2023-08-03 US disclosed
WO-2017172763-A1 SYNTHESIS AND APPLICATION OF CHIRAL SUBSTITUTED POLYVINYLPYRROLIDINONES KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) 2017-10-05 WO disclosed
US-20160250270-A1 COMPOSITIONS COMPRISING COMBINATIONS OF PURIFIED CANNABINOIDS, WITH AT LEAST ONE FLAVONOID, TERPENE, OR MINERAL CANOPY GROWTH CORPORATION (CA) 2016-09-01 US disclosed
US-20140363530-A1 COMPOSITION COMPRISING THE EXTRACT OF PINE TREE LEAF OR THE COMPOUNDS ISOLATED THEREFROM FOR THE PREVENTION AND TREATMENT OF CANCER DISEASE BY INHIBITING HPV VIRUS AND THE USES THEREBY GUEULRI (KR) 2014-12-11 US disclosed
US-8057829-B2 Methods for repelling insects using sesquiterpene hydrocarbons and their derivatives STERLING INTERNATIONAL INC. (US) 2011-11-15 US disclosed
US-8057829-B2 Methods for repelling insects using sesquiterpene hydrocarbons and their derivatives STERLING INTERNATIONAL INC. (US) 2011-11-15 US disclosed
US-20100166896-A1 METHODS FOR REPELLING INSECTS USING SESQUITERPENE HYDROCARBONS AND THEIR DERIVATIVES STERLING INTERNATIONAL INC. (US) 2010-07-01 US disclosed
US-20100166896-A1 METHODS FOR REPELLING INSECTS USING SESQUITERPENE HYDROCARBONS AND THEIR DERIVATIVES STERLING INTERNATIONAL INC. (US) 2010-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100166896-A1 METHODS FOR REPELLING INSECTS USING SESQUITERPENE HYDROCARBONS AND THEIR DERIVATIVES CYP51A1, LSS, DAGLA CYP3A4 2204/4885FTH1 693/4885CYP2C9 820/4885
US-20230242569-A1 PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS PPIP5K2, INPP5B, PTMS CYP3A4 321/4885FTH1 1397/4885CYP2C9 560/4885
US-20240066005-A1 FORMULATIONS FOR TREATING CLUSTER SYMPTOMS ASSOCIATED WITH AUTISM SPECTRUM DISORDER CNR2, CNR1, GPR18 CYP3A4 1869/4885FTH1 3595/4885CYP2C9 2084/4885
US-20140363530-A1 COMPOSITION COMPRISING THE EXTRACT OF PINE TREE LEAF OR THE COMPOUNDS ISOLATED THEREFROM FOR THE PREVENTION AND TREATMENT OF CANCER DISEASE BY INHIBITING HPV VIRUS AND THE USES THEREBY VHL, TP53, PNN CYP3A4 2451/4885FTH1 4241/4885CYP2C9 3408/4885
US-20160250270-A1 COMPOSITIONS COMPRISING COMBINATIONS OF PURIFIED CANNABINOIDS, WITH AT LEAST ONE FLAVONOID, TERPENE, OR MINERAL CNR2, CNR1, MAG CYP3A4 1000/4885FTH1 3532/4885CYP2C9 1487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.